30 Technology completes final patient dosing in its TB study in South Africa 30 Technology is excited to announce that we have successfully completed the final dosing for all participants enrolled in our Tuberculosis study based in South Africa. 30 Technology Holds Inaugural Scientific Advisory Board Meeting We are delighted to announce the first meeting of 30 Technology’s newly formed Scientific Advisory Board (SAB) held in our offices in Central London. 30 Technology launches a critical clinical trial in patients with newly diagnosed tuberculosis We are delighted to announce that our latest clinical trial ‘RESP30X-EBA’ is active and recruiting at the TASK Clinical Research Centre, South Africa. 30 TECHNOLOGY: DELIVERING THE FULL POTENTIAL OF THERAPEUTIC NITRIC OXIDE 30 TECHNOLOGY is developing nitric oxide-generating technologies for a range of health care applications Watch video